Analysis of Primary-Refractory Hodgkin Lymphoma Pts in a Randomized, Placebo-Controlled Study of Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplant.
Analysis of Primary-Refractory Hodgkin Lymphoma Pts in a Randomized, Placebo-Controlled Study of Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplant.
Clin Adv Hematol Oncol. 2015 Aug;13(8 Suppl 9):14-5
Authors:
PMID: 26862874 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
More News: Cancer & Oncology | Hematology | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants